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Purpose: Evidence of a genetic predisposition tothe development of inflammatory abdom- 
inal aortic aneurysms (AAAs) exists as a positive family history in 17% of patients. 
Familial clustering and other similarities between inflammatory AAAs and giant cell 
arteritis (GCA), which possesses a genetic risk determinant mapped to the HLA-DR 
molecule, suggest arole of genetic risk factors in inflammatory AAAs. The purpose of this 
study was to explore whether patients with inflammatory AAAs express disease-relevant 
genes associated with the tILA-DR region on the short arm of chromosome 6.
Methods: Thirty-seven patients with histomorphologic findings of inflammatory AAA at 
operation were genotyped for the polymorphism of the HLA-DR BI and HLA-DQ BI 
alleles and compared to ethnically matched, healthy control subjects (n = 90). 
Results: Distribution of HLA-DR BI alleles was nonrandom in patients with inflamma- 
tory AAAs versus control subjects. The HLA-DR B1 alleles BI*I5 and BI'0404 were 
enriched in patients with inflammatory AAAs compared with control subjects (47% 
versus 27%, and 14% versus 3%; p < 0.05, respectively). Analysis of ftmctionally relevant 
amino acid polymorphisms encoded by the HLA-DR BI gene showed relevance at amino 
acid position 70. HLA-DR BI alleles overrepresented in patients with inflammatory 
AAAs express a glutamine substitution at position 70, whereas alleles disfavored in the 
patient cohort express a negatively charged aspartic acid. Distribution of HLA-DQ BI 
alleles were indistinguishable in patients and control subjects. 
Conclusion: These data indicate that a genetic risk determinant can be mapped to the 
HLA-DR BI locus in patients with inflammatory AAAs. This association suggests a 
critical contribution of antigen binding in the pathogenesis of this disease. (J Vasc Snrg 
1997;25:356-64.) 
Inflammatory abdominal aortic aneurysms 
(AAAs) were originally described by Walker et al. 1 
and represent 2% to 14% of all AAAs? -6 As we have 
recently reviewed, they are defined by the triad of 
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thickened aneurysm wall, extensive perianeurysmal 
and retroperitoneal fibrosis and inflammation, and 
dense adhesions of adjacent abdominal organs (Fig. 
1). 1-3 Patients frequently have the symptoms of fa- 
tigue, malaise associated with abdominal or back 
pain, and an elevated sedimentation rate. 6 The mean 
age of patients with inflammatory AAAs is 65 years, 5 
to 10 years younger than patients with noninflamma- 
tory ~AAs.  1-6 
We and others have shown indirect evidence for 
the role of genetic factors in the development of 
inflammatory AAAs. 2,7 A positive family history of 
aneurysms exists in 17% of patients, and clinical ex- 
perience suggests clustering of these aneurysms in 
northern Europeans. 7 In addition, these anenrysms 
have a distinct tendency to occur in men. 2-7 These 
observations strongly suggest a role for genetic risk 
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factors in their dcvelopmcnt; however, to date no 
direct evidence identifying a specific genetic risk de- 
terminant has been shown. 
Although the cause of inflammatory AAAs is un- 
known, recent studies from Pearce et al.12 and Tilson 
et al.,41 as well as others, have provided insight into 
the pathogenesis of both inflammatory and nonin- 
flammatory AAAs. TM These studies reveal several 
features that indicate an ongoing destructive im- 
mune response in the aortic wall. TM Specifically, 
these studies and others have shown an immune 
process characterized byaortic wall-infiltrating mac- 
rophages, T lymphocytes (enriched in the CD4 + 
population), and B lymphocytes. 1°,12,13 Production 
of important cytoldnes and cellular adhesion mole- 
cules has been shown to be increased in aneurysmal 
aortic wall. 14-16 These cytokines and adhesion mole- 
cules lead to activation of proteolytic activity in the 
form ofmetalloproteinases, 8,9,17 which increase turn- 
over of the matrix proteins, elastin, and collagen.18-2 
Subsequent loss of aortic wall integrity and tensile 
strength occurs as an aneurysm forms? aThis inflam- 
matory process appears to be accentuated in certain 
predisposed persons, and an inflammatory AAA de- 
velops at a relatively younger age. Also of interest, a
high percentage ofparients with inflammatory AAAs 
are current smokers, raising the question of the influ- 
ence of tobacco n the pathogenesis of this disease. 7 
In searching for a unified hypothesis forthe for- 
mation of inflammatory AAAs, we have been im- 
pressed with their similarity to another arterial dis- 
ease, giant cell arteritis (GCA). Inflammatory AAAs 
share clinical nd histopathologic s milarities to GCA 
that, like aneurysms, how a tissue tropism for the 
medium and large arteries of the body. 22 Similar to 
patients with inflammatory aneurysms, patients with 
GCA frequently have symptoms of fatigue, fever, 
weight loss, and an elevated sedimentation rate, 
likely mediated by a systemic component of the in- 
flammatory process. 22,23 Also common to these two 
arterial diseases is the clustering of disease among 
certain ethnic groups and or within families. 
As in patients with inflammatory AAAs, studies in 
patients with GCA show that the large arteries are 
involved with tissue-infiltrating inflammatory cells, 
mainly T lymphocytes and macrophages, which cen- 
ter their immune process in the media of the arterial 
wall. 2426 This inflammation i  the arteries in GCA is 
associated with the destruction f the smooth muscle 
layer and fragmentation f the internal elastic lamina. 
Weyand et al.26,27 and Wagner et al.28 showed that 
the inflammatory process within the vessel wall is 
directed by CD4 + helper T lymphocytes a well as by 
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Fig. 1. Illustration of inflammatory abdominal aortic n- 
eurysm (AAA) with adherent, adjacent abdominal orga s.
macrophage activation. Molecular analysis of tissue 
infiltrating T cells has indicated that identical T cells 
proliferate at anatomically distinct sites of the inflam- 
matory process. The most likely explanation for the 
activation of selected T cells in the tissue is the 
recognition of a tissue-residing antigen. 29 
Weyand et al?0 showed direct evidence of a ge- 
netic risk determinant in the development of GCA 
that exists on the HLA-DR molecule within the class 
II major histocompatibility complex. The important 
location of this genetic determinant within the anti- 
gen binding groove of the HLA-DR molecule also 
suggests hat antigen binding and presentation to the 
T lymphocyte is a critical event in the cause and 
pathogenesis of GCA. On the basis of the clinical and 
histopathologic similarities between GCA and in- 
flammatory AAAs, we hypothesize that similar ge- 
netic risk determinants may exist that predispose per- 
sons to the development of inflammatory AAAs. 
Because of the distinct nature of these two diseases, 
we also hypothesize that the genetic risk determinant 
that exists for patients with inflammatory AAAs is 
distinct from and exists on a different location of the 
HLA-DR molecule than that for GCA. Characteriza- 
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Table I. Demographic and clinical 
characteristics of patients with 
inflammatory AAA 
Patients with 
inflammatory 
AAA 
(n= 37) 
Age at operation (yr) 68 
Sex (% male) 77 
Smoker (% former or present) 89 
Family history of aneurysms (%) 22 
Peripheral vascular disease (%) 32 
Coronary artery disease (%) 35 
COPD (%) 40 
Hypertension (%) 66 
Elevated sedimentation rate (%) (16/23) 70 
Aneurysm size (mean, cm) 6.8 
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive 
pulmonary disease. 
tion of its location on the HLA molecule may allow 
for predictions on the nature of the immunogenic 
peptide bound in inflammatory AAAs and thus facil- 
itate the Search for disease-relevant tigens. 
METHODS 
Patients. Patients with classic recognizable in- 
flammatory abdominal aortic aneurysms at the time 
of operation were entered into group I (n = 37). 
Patients in whom the diagnosis of inflammatory ver- 
sus noninflammatory AAA was in question at the 
time of operation were excluded from the study pop- 
ulation. No patients were excluded on the basis of 
race or sex. 
Table I shows the demographics of the patient 
population (n = 37) with inflammatory AAAs. 
Ninety normal individuals were recruited as control 
subjects (group 2). All patients in group 1 and con- 
trol subjects in group 2 were white. None of the 
control subjects used had any history of autoimmune 
disease. Persons with a family history of an inflamma- 
tory rheumatic disease were excluded. 
DNA analysis. The HLA-DR B1 alleles were 
determined by amplification of DNA extracted from 
peripheral blood mononuclear cells with primer sets 
specific for the allelic variants at the HLA-DR B1 
locus, followed by oligonucleotide hybridization to 
identify sequence variants amongst the allelic prod- 
ucts. A polymerase chain reaction (PCR) with 30 
cycles was used under the following conditions: de- 
naturation for 30 seconds at 94 ° C, annealing for 30 
seconds at 55 ° C, and extension for 30 seconds at 
72 ° C. To identify sequence polymorphisms en- 
coded by the second and third hypervariable r gion 
of the HLA-DR B1 alleles, amplified products were 
blotted onto nitrocellulose membranes and hybrid- 
ized with biotin-labeled oligonucleotide probes spe- 
cific for sequence polymorphisms ofthe different DR 
B1 alleles and subsequently developed with strepta- 
vidine-alkaline phosphatase r action. The primer sets 
and the nucleotide probes used for the identification 
of the HLA-DR B1 alleles have been described pre- 
viously.28, 31 
HLA-DQBI alleles were determined by a nested 
PCR approach. DNA from peripheral mononuclear cells 
was amplified with a DQBl-specific primer (TGCCCG- 
CAGAGGATTTCGTG) and the HLA-DQ B1 
group-specific primers (DQ B1"02/03/04, TG- 
CAAGGTCGTGCGGAGCT; DQ B1 *05/06, ATC- 
CCGCGGTACGCCACCTC) under the following 
conditions: denaturation for 30 seconds at 94 ° C, 
annealing for 30 seconds at 62 ° C, and extension for 
1 minute at 72 ° C. The amplified products were 
adjusted, diluted, and reamplified with the HLA- 
DQ B/-specific primer and the appropriate 
HLA-DQ Bl-allele-specific primers (HLA-DQ 
BI *02, GTCCACCGCCGCCCGTTT; DQ B1 *03, 
CTCGCACACCGTGTCCAACTC; DQ B1"05, 
TCTGCACACCCTGTCCACCGA; DQ B1"06, 
TCTGCACACCGTGTGGAACTCG). To type for 
HLA-DQB2 *04, the appropriate PCR product was 
amplified with the HLA-DQ B1"02/03/04 group- 
specific primer and an HLA-DQ Bl*O4-specific 
primer (ACCGAGCTCGTGCGGG). Each PCR in- 
cluded negative controls and DNA from lymphoblas- 
toid cell lines from the Tenth International Histo- 
compatibility Workshop as positive controls. 
Statistical analysis. The frequencies of HLA- 
DR B1 alleles in patients and in control subjects were 
compared by ×2 test or Fisher's exact probability test 
as appropriate. Significance was defined a p value of 
less than 0.05. 
RESULTS 
Distribution of  HLA-DR B1 alleles in pa- 
tients with inflammatory AAAs. As shown in Fig. 
2, the HLA-DR B1 locus encodes for highly poly- 
morphic molecules. The alleles HLA-DR B1 "01, 15, 
03, 04, 11, 07, and 13 are normally present in similar 
frequencies and are expressed by 20% to 25% of 
persons in a normal population. Alleles such as 
HLA-DR B1 *08, 09, 10, and 14 are less frequent and 
are detected in 2% to 10% of all white donors. Con- 
versely, patients with inflammatory AAAs display a 
nonrandom distribution of HLA-DR B1 alleles. 
The most frequent HLA-DR B1 variant among 
the patients with inflammatory AAAs was HLA-DR 
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Fig. 2. Frequency of HLA-DR B1 alleles in patients with Inflammatory AAAs versus control 
subjects. 
Bl "15, which was expressed in 46% of the patient 
cohort. This accumulation of HLA-DR B1 "15 do- 
nors in the patient population reached statistical sig- 
nificance (p = 0.035) compared with control sub- 
jects. In addition, a higher proportion of patients 
with inflammatory AAAs had inherited an HLA-DR 
B1 *04 allele, with 35% of patients typing positive for 
this allele. This trend did not reach statistical signifi- 
cance. The HLA-DR B1 *04 family includes a cluster 
of alleles that differ by minor sequence differences in 
the third hypervariable region of the gene. In the 
white population, HLA-DR B1"0401 is the most 
frequent allelic variant, followed by HLA-DR 
B1 *0404, 0402, and 0403. Patients with inflamma- 
tory AAAs who are positive for HLA-DR B1 *04 
transcribed an 0401 and 0404 allele in similar fre- 
quency (Fig. 2). This finding indicates that HLA-DR 
B1 *0404 individuals are enriched in the patient pop- 
ulation. This enrichment reached statistical signifi- 
cance (p = 0.032) compared with control subjects. 
Thus patients in whom inflammatory AAAs develop 
are selected for the polymorphism oftheir HLA-DR 
B1 gene, with an increased risk for HLA-DR B1 "15 + 
and HLA-DR B1 *0404 +. 
In patient cohorts with a biased istribution of 
HLA-DR B1 genes, acompensatory decrease of non- 
disease-associated alleles can be expected. As shown 
in Fig. 2, a decrease in allele frequencies in patients 
with inflammatory AAAs also followed a nonrandom 
pattern. Patients with inflammatory AAAs have a 
decreased chance of typing HLA-DR B1 "13, 08, 11, 
and 01. The frequencies of HLA-DR B1 *03 and 07 
were nearly indistinguishable b tween patients and 
control subjects. This pattern of HLA-DR B1 alleles 
expressed among the patients uggests hat the asso- 
ciation of the disease with selected HLA-DR B1 
alleles does not simply reflect the increased isease 
risk of carriers of a single HLA-DR B1 allele. 
Nonrandom selection of position 70 in the 
HLA-DR B1 gene in inflanunatory AAA patients. 
The major biologic function of HLA-DR molecules 
is to bind and present antigenic peptides for recogni- 
tion by the T-cell receptor. The binding function is 
facilitated by accommodating polypeptide side 
chains in highly polymorphic binding pockets that 
arc clustered in an antigen-binding cleft. The se- 
quence polymorphisms characteristic for HLA-DR 
B1 alleles transfer into polymorphic sites, shaping the 
antigen-binding pockets. One of the important bind- 
ing pockets, pocket 4, has been mapped to include 
the amino acid positions 67, 70, 71, and 74. Pocket 
4 extends from the floor of the antigen-binding 
groove to the wall formed by an ~ helix. As noted, 
within binding pocket 4, amino acid positions 70 is 
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Favored Alleles 
Bl*15  
B1"0404 
Disfavored Alleles 
BI* l l  F/I 
B l *08  
B l *13  
BI*01 
Amino Acid Position in Pocket 4 
67 71 74 
I A A 
L R A 
E/R A 
I R A 
I E/R A 
L Q a A 
Fig. 3. Amino acid sequences of the favored and disfa- 
vored alleles in patients with inflammatory AAAs. 
located in a critical position at the entrance of the 
pocket. In many HIM-DR B1 alleles, position 70 is a 
negatively charged aspartic acid that favors interac- 
tion with positively charged peptide ligands. Alterna- 
tively, the HIM-DR B/-encoded [3 chain may ex- 
press a noncharged glutamine in position 70. 
Because of differences in the charge of these two 
possible substitutions, the binding characteristics can 
change dramatically, depending on whether position 
70 holds an aspartic acid or glutamine. 
To examine the potential role of antigen-binding 
pockets in patients with inflammatory AAAs, 
HLA-DR B1 alleles were analyzed for the sequence 
polymorphisms in positions 67, 70, 71, and 74. All 
of these positions are localized in the central region 
of HLA-DR-antigen interaction. As shown in Fig. 3, 
the two allelic variants enriched in the patient popu- 
lation shared a glutamine substitution (Q) in posi- 
tion 70. Conversely, three of the four alleles disfa- 
vored in the patient population expressed an 
aspartate substitution (D) in position 70. None of 
the other amino acids in polymorphic sites were 
informative in dissection of the two sets of alleles. 
The dichotomy that exists for position 70 in the 
inflammatory AAA group was not maintained for 
one of the alleles that occurred with decreased fre- 
quency in patients compared with control subjects, 
HIM-DR B1 *01. 
Allelic combinations at the HLA-DR B1 locus 
in patients with inflammatory aAAs. Whenever 
two different alleles are associated with a disease 
process, the question arises whether patients who 
combine both alleles have a higher risk of develop- 
ment of the disease. To approach this question, the 
genotype data were analyzed for patients who ex- 
pressed both an HLA-DR Bl*15 allele and an 
HLA-DR B1 *0404 allele. Only one patient was 
heterozygous for HLA-DR B1 "15 and 0404, indi- 
cating the lack of additive affects of both disease- 
associated haplotypes. In addition, no patients 
were typed as HLA-DR B1 "15 homozygous and 
one patient was genotyped as HLA-DR B1 *0404/ 
0404. Obviously, a single susceptibility allele is 
sufficient to confer isk. 
Patients who lacked both HLA-DR B1 "15 and 
B1 *0404 frequently expressed HLA-DR3 haplotype. 
More significantly, among the 10 patients who were 
negative for HLA-DR B1"15 and BI'0404, three 
were homozygous for HLA-DR B1 *03. Within the 
group of 90 white control subjects, only two persons 
were observed who were homozygous for HLA-DR 
B1 *03. 
Clinical characteristics of  patients with en- 
riched HLA-DR B1 alleles. The identification of 
two distinct alleles associated with the disease and the 
lack of additive effects of these two haplotypes sug- 
gests as one possibility that the patient cohort in- 
cludes persons with two subtypes of disease. To ex- 
plore this possibility, patients who type HLA-DR 
B1"15 + or HLA-DR B1"04 + were compared for 
clinical characteristics. The results of this comparison 
are given in Table II. Expression of the HLA-DR 
B1 "15 or HLA-DR B1 *0404 did not affect he age at 
diagnosis or sex. Although the use of tobacco was 
common in the patient population in general, it is 
intriguing to note that 100% of the patients who 
typed positive for HIM-DR B1 "15 had a history of 
tobacco use. Furthermore, a higher percentage 
(60%) of patients smoked until the time of their 
diagnosis. Although statistical nalysis of these obser- 
vations of tobacco use in the HLA-DR B1"15 + 
group did not reach significance compared with the 
HLA-DR B1 *04 + and BI "15-/t31 *04- groups, we 
believe that they represent interesting trends, possi- 
bly indicating the combination of genetic and envi- 
ronmental risk factors in the disease process. Also 
common in the HLA-DR B1 "15 + group was the 
presence of an elevated erythrocyte sedimentation 
rate in 90% of patients, suggesting a more severe or at 
least a systemic omponent of the disease. Of note, 
this is the same group that had the prominent history 
of tobacco use. The presence of an elevated erythro- 
cyte sedimentation rate in the HIM-DR B1 "15 + 
group compared with e HLA-DR B1 *04 + group 
reached a p value of 0.04. Although statistical signif- 
icance of some of these trends was lacldng, the power 
of the analysis may have been limited by the number 
of patients in each of the subgroups; therefore these 
trends warrant further investigation with larger pa- 
tient populations. 
In contrast, a characteristic observed frequently 
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Table II. Clinical characteristics of patients with enriched HLA-DRB1 alleles 
DR B2 "15 + DR B1 *04 + BI *15-BI *04- 
(n = 17) (n = 10) (n = 10) p Value 
Age (yr) 70 70 66 0.7 
Sex (% male) 76 80 70 0.8 
Smoker (% ever) 100 80 80 0.1 
Smoker (% current) 60 40 40 0.5 
Family history of aneurysms (%) 12 40 20 0.4 
Elevated ESR (%) 90 33 71 0.04* 
Aneurysm size (cm) 6 6.6 6.2 0.4 
ESR, Erythrocyte sedimentation rate. 
*p < 0.05 between 15 + and 04 +. 
in the HLA-DR B1 *04 group was that of a family 
history of aneurysms. Forty percent of patients with 
inflammatory AAAs who typed positive for HLA-DR 
B1 *04 reported a family history of aneurysms. This 
was nearly two times the rate of the population in 
general and more than three times the reported rate 
in the HLA-DR B1 "15 + group. These observations 
suggest allele-specific characteristics--that HLA-DR 
B1 "15 + patients have a lower rate of family history 
but require the use of tobacco to promote the dis- 
ease--whereas the HLA-DR B1 *04 patients have a 
greater prevalence of family history and do not re- 
quire the use of tobacco to promote the develop- 
ment of inflammatory AAAs. 
Frequencies of  the HLA-DQ B1 alleles in pa- 
tients with inflammatory AAAs. HLA-DR B1 
genes are highly polymorphic but are inherited 
within a cluster ofpolymorphic genes in the HLA-D 
region located on the short arm of chromosome 6.
The linkage disequilibrium within the HLA-D re- 
gion raises the question of whether aparticular locus 
or a locus in the near vicinity is the disease-associated 
element. For this reason, we xtended our studies to 
the HLA-DQ B1 gene. Allele-specific amplification 
with nested sets of primers was used to assign 
HLA-DR QBI genes to each of the 37 patients and 
30 control subjects. The results are presented in 
Table III. The distribution of the HLA-DQB1 genes 
was essentially indistinguishable in both study co- 
horts. The association of inflammatory AAAs with 
allelic variants of the HLA-DR B1 locus and the lack 
of an association with the HLA-DQ BI locus lend 
further support o the importance of HLA-DR mol- 
ecules in the disease process. 
DISCUSSION 
Histocompatibility proteins are cell surface pro- 
teins that bind antigenic peptides intracellularly and 
present them at the cell surface for interaction with T 
lymphocytes 32,33 that, once activated, irect local in- 
Table III. Frequencies of HLA-DQ B1 
alleles in patients with inflammatory AAA 
and in Normal subjects 
Patients with 
inflammatory 
AAA Control subjects 
HLA-DQB1 (n = 37) (n = 33) 
allele % % p Value 
DQBI  *02 46 3O NS 
DQBI  *03 64 54 NS 
DQB1 *04 3 12 NS 
DQB1 *05 14 24 NS 
DQB1 *06 46 45 NS 
NS, Not significant. 
flammation by secretion of cytoldnes uch as inter- 
leuldn-2 and interferon-y. This process is an impor- 
tant part of the immune response to foreign 
antigen. 32,a3 Class II histocompatibility or HLA 
molecules are expressed by specialized antigen-pre- 
senting cells such as macrophages and dendritic ells. 
Class II HLA molecules contain two different 
polypeptide chains, designated ~ and [3, and are en- 
coded by genes within the D region of the HLA 
complex located on chromosome 6.34,3s In humans, 
this D region is divided into at least three subregions: 
DP, DQ, and DR. Each of these subregions contains 
at least one c~ gene and one [3 gene. The ci and 13 
chains come together as a heterodimer, which forms 
an antigen-binding cleft. The floor of the antigen- 
binding cleft is composed of eight antiparallel 
13-pleated sheets, whereas the side walls of the cleft 
are formed by ~ helixes. 35 Amino acid p0tymorphism 
within the 13 chain of the HLA-DR molecule and the 
o~ and 13 chains of the HLA-DQmolecule within the 
antigen-binding cleft mediates variations in the im- 
mune response of different individuals to different 
antigens and contributes to disease susceptibility. 36 
Within the antigen-binding cleft of the HLA-DR 
molecule are several small, highly polymorphic bind- 
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Fig. 4. Computer-generated model of the HIM-DR 
molecule with the giant cell arteritis (GCA) pocket high- 
lighted. (Reproduced with permission from Stern LJ, 
Brown JH, Jardetsky TS, et al. Nature 1994;368:215-21. 
Copyright 1994 Macmillan Magazines Limited.) 
Fig. 5. Computer-generated model of the HLA-DR 
molecule with pocket 4 highlighted (Modified from Stern 
LJ, Brown JH, Jardetzlcy TS, et al. Nature 1994;368:215- 
21. Copyright 1994 Macmillan Magazines Limited. Used 
with permission.) 
ing pockets. Specifically, five of these pockets appear 
to be important in accommodating side chains of 
antigenic peptides. 37 These polymorphic amino acid 
residues that line the side-chain binding pockets are 
responsible for the different peptide specificities of 
different HLA-DR B1 alleles. Fig. 4 shows a com- 
puter model of the HI.,A-DR molecule, looking 
down into the antigen-binding cleft. The dotted line 
represents the nonpolymorphic c~ chain, and the 
solid line represents he polymorphic [3chain. High- 
lighted is the amino acid sequence, which has been 
mapped as the genetic risk determinant in patients 
with GCA. The GCA pocket exists on the floor of the 
antigen-binding cleft of the HLA-DR molecule. 
Because the inflammatory infiltrate in the arterial 
wall of patients with aneurysms suggests an ongoing 
immune response and because of the similarities be- 
tween inflammatory AAAs and GCA, we explored in
this study the HLA or immune response gene in 
patients with inflammatory AAAs. Our findings sug- 
gest an important contribution of amino acid posi- 
tion 70 of the HIM-DR B1 chain, which is critically 
positioned at the entrance of binding pocket 4, ex- 
tending from the floor of the antigen-binding cleft to 
one of the o~ helixes highlighted on the computer 
model in Fig. 5. This important location in the 
HIM-DR molecule accommodates side chains of an- 
tigenic peptides that interact with the HIM-DR mol- 
ecule. Substitution of a Gin for a negatively charged 
Asp at the entrance to pocket 4 significantly changes 
the binding behavior of the pocket and therefore 
changes antigen selection. 
Glutamine in a physiologic environment is most 
commonly a noncharged but polar amino acid. It can 
function as a hydrogen bond donor and may be 
found on the surface of or buried within a protein 
structure. Because of its relative compact nature, it is 
frequently found in e~ helixes. In contrast, aspartic 
acid is an acidic, negatively charged amino acid that is 
quite polar. Because of its charge, it is located more 
frequently on the surface of peptide structures. As- 
partic acid can function as a hydrogen bond acceptor 
but is preferentially involved in protein-protein inter- 
actions by forming salt bridges. Enrichment of the 
expression of glutamine at position 70 therefore 
would change significantly the binding behavior of 
pocket 4 to side chains of antigenic peptides that 
interact with the HLA-DR molecule. Furthermore, 
this substitution at position 70 of pocket 4 likely 
changes its structural conformation and size. This 
finding in patients with inflammatory AAAs strongly 
suggests a critical role of antigen binding in the 
origin of this disease, and its distinct location on the 
HLA-DR molecule suggests disease specificity com- 
pared with GCA. 
The cause of inflammatory AAAs remains an 
enigma. It appears that the cause is multifactorial: a 
combination of genetic, environmental, and endo- 
thelial factors that results in an antigen-driven, de- 
structive inflammatory process in the arterial wall of 
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susceptible persons. Speculation regarding the anti- 
gen responsible for this process includes both endog- 
enous and exogenous products. Breakdown products 
ofelastin or red blood cells and oxidized low-density 
lipoproteins have been suggested asendogenous anti- 
gens. 384° A recent study by Tilson 4~ that used im- 
munoglobulin- and amino acid-sequencing tech- 
niques provides evidence that an endogenous 
autoantigen xists in aneurysmal disease that is simi- 
lar to a microfibril-associated glycoprotein and raises 
the question ofautoimmunity as an important mech- 
anism in the pathogenesis of ancurysms.  41,42 Tanaka 
et al. 4a,44 published evidence that the cytomegalo- 
virus may play a role as an exogenous antigen in the 
pathogenesis of aortic diseases. 
Regardless of the antigen, the observation of to- 
bacco use among the HLA-DR Bl*15 + patients 
raises questions about its influence as a possible envi- 
ronmental promoter of the destructive inflammatory 
response resulting in inflammatory AAAs. This is a 
particularly appealing hypothesis, given that a high 
number of patients in the same group had elevated 
erythrocyte s dimentation rates. This evidence isob- 
servational in nature and does not offer mechanism; 
however, it is an pertinent observation that deserves 
further investigation both in larger clinical numbers 
of patients and in in vitro studies. 
In summary, these findings upport the studies of 
Drs. Pearce and Tilson and others who suggest that 
aneurysms may occur as an antigen driven inflamma- 
tory response within the arterial wall. In addition, 
these findings provide for the first time direct evi- 
dence of a genetic risk determinant to the develop- 
ment of inflammatory AAAs. Furthermore, they raise 
questions about he possible actions of tobacco use 
as an environmental promoter of this disease. Finally, 
this study extends the studies of Tanaka et al. 43,44 and 
others who provide possible antigenic instigators of 
the inflammatory esponse and, for the first time, 
allows characterization f actual antigen structure 
and charged composition. Studies uch as this, char- 
acterizing the HLA molecule, may allow future pre- 
dictions on the nature of antigenic epitopes of the 
selected immunogenic peptide bound and thus facil- 
itate the search for disease-relevant antigens. 
In conclusion, patients with inflammatory AAAs 
possess a genetic risk determinant that can be 
mapped to the HLA region. Specifically, patients 
with inflammatory AAAs preferentially express a neu- 
trai charge at the entrance of binding pocket 4 of the 
HLA-DR molecule. This localization of the genetic 
risk determinant distinguishes inflammatory A_AAs 
from another HLA-DR-associated inflammatory 
disease that targets the wail of large arteries, GCA. 
Distinct polymorphic domains of the HLA-DR mol- 
ecule are associated with inflammatory abdominal 
aortic aneurysms and giant cell arteritis, uggesting 
disease specificity. The role of different binding pock- 
ets in inflammatory abdominal ortic aneurysms and 
giant cell arteritis i compatible with a contribution 
of different antigens in disease pathogenesis. Further 
studies that combine clinical data with more xten- 
sive characterization f the HLA molecule may lead 
to the identification ofdisease-relevant antigens and 
environmental promoters of their pathogenesis. 
We acknowledge the illustrative expertise of David A. 
Factor and the statistical ssistance of James W. Fulbright. 
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